Crossmark

Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir

Crossref DOI link: https://doi.org/10.1186/s12977-018-0440-3

Published Online: 2018-08-17

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

,

Oliveira, Maureen

Ibanescu, Ruxandra-Ilinca

Anstett, Kaitlin

Mésplède, Thibault

Routy, Jean-Pierre

Robbins, Marjorie A.

Brenner, Bluma G. https://orcid.org/0000-0002-2084-728X
Funding

Funding for this research was provided by:

Gilead Sciences (9883)

Fonds de Recherche du Quebec (202685)

Genome Canada and Quebec (142HIV)
License Information

Text and Data Mining valid from 2018-08-17
More Information

Article History

Received: 5 July 2018

Accepted: 11 August 2018

First Online: 17 August 2018